{"entity":{"id":"neeraj-agarwal","kind":"person","name":"Neeraj Agarwal","aka":[],"tldr":"GU oncologist who led TALAPRO-2 and other trials combining PARP inhibitors with hormone therapy.","summary":"Neeraj Agarwal is SWOG Executive Officer for Genitourinary and Early Therapeutics and Professor of Medicine at the Huntsman Cancer Institute, University of Utah. A medical oncologist specialising in prostate and kidney cancer and targeted therapy, he was principal investigator of TALAPRO-2, the trial of talazoparib plus enzalutamide, and of CONTACT-03. His papers report the TALAPRO-2 randomised, placebo-controlled phase 3 trial in first-line metastatic castration-resistant prostate cancer in the Lancet and the design of CONTACT-02, a phase III study of cabozantinib plus atezolizumab versus a second novel hormone therapy in the same disease. He directs genitourinary oncology at Huntsman and works on PARP and the androgen receptor in prostate and renal cell carcinoma.","asOf":"2026-09-08","links":[{"label":"SWOG leadership","url":"https://www.swog.org/about/leadership"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Agarwal%20N%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=Neeraj%20Agarwal"}],"tags":[],"related":[],"cancers":["prostate","rcc"],"sections":[],"technologies":[],"targets":["parp","androgen-receptor"],"drugs":["talazoparib"],"companies":["swog"],"institutions":[],"pathways":[],"terms":[],"trials":["talapro-2","contact-03"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["future-oncology"],"dependsOn":[],"notes":[],"role":"SWOG Executive Officer, Genitourinary and Early Therapeutics; Professor of Medicine, Huntsman Cancer Institute, University of Utah","institutionId":"swog","specialisms":["Prostate cancer","Kidney cancer","Targeted therapy"],"profiles":[{"label":"SWOG leadership","url":"https://www.swog.org/about/leadership"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Agarwal%20N%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=Neeraj%20Agarwal"}],"papers":[{"title":"Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial","journal":"Lancet","year":2023,"url":"https://doi.org/10.1016/S0140-6736(23)01055-3","doi":"10.1016/S0140-6736(23)01055-3"},{"title":"A Phase III, Randomized, Open-Label Study (CONTACT-02) of Cabozantinib Plus Atezolizumab Versus Second Novel Hormone Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer","journal":"Future Oncology","year":2022,"url":"https://doi.org/10.2217/fon-2021-1096","doi":"10.2217/fon-2021-1096"}]},"route":"/people/neeraj-agarwal/","neighbours":{"cancer":[{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"},{"id":"rcc","kind":"cancer","name":"Renal cell carcinoma","route":"/cancers/rcc/"}],"target":[{"id":"androgen-receptor","kind":"target","name":"Androgen receptor","route":"/targets/androgen-receptor/"},{"id":"parp","kind":"target","name":"PARP","route":"/targets/parp/"}],"drug":[{"id":"talazoparib","kind":"drug","name":"Talazoparib","route":"/drugs/talazoparib/"}],"company":[{"id":"swog","kind":"company","name":"SWOG Cancer Research Network","route":"/companies/swog/"}],"trial":[{"id":"contact-03","kind":"trial","name":"CONTACT-03","route":"/trials/contact-03/"},{"id":"talapro-2","kind":"trial","name":"TALAPRO-2","route":"/trials/talapro-2/"}],"journal":[{"id":"future-oncology","kind":"journal","name":"Future oncology","route":"/journals/future-oncology/"}],"institution":[{"id":"huntsman","kind":"institution","name":"Huntsman Cancer Institute, University of Utah","route":"/institutions/huntsman/"}]}}